Quantum computers—devices that process information using quantum mechanical effects—have long been expected to outperform classical systems on certain tasks. Over the past few decades, researchers ...

Abstract: This paper on the systematization of experiences aims to discuss the potential of Game Jams as an experiential learning activity in the region, focusing on the experience of the CIDeV ...

Something strange happened at University of California campuses this fall. For the first time since the dot-com crash, computer science enrollment dropped. System-wide, it fell 6% last year after ...

China’s brain-computer interface industry is growing fast, and the newest company to emerge from the country is aiming to access the brain without the use of invasive implants. Gestala, newly founded ...

If you are interested in historical big computers, you probably think of IBM, with maybe a little thought of Sperry Rand or, if you go smaller, HP, DEC, and companies like Data General. But you may ...

Almost everyone has a PC or laptop of some kind, but in the future, you might not own one anymore. According to Jeff Bezos, the idea of personal computers may not last much longer. In his 2024 ...

Suchandrima Bhowmik has written over 300 articles on various health conditions, medical news, and recent breakthroughs. Her work appears in several publications, including Medical News Today, ...

Carrie Madormo, RN, MPH, is a health writer. She has over a decade of experience as a registered nurse, practicing in a variety of fields, such as pediatrics, oncology, chronic pain, and public health ...

The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...

Designed to accelerate advances in medicine and other fields, the tech giant’s quantum algorithm runs 13,000 times as fast as software written for a traditional supercomputer. A quantum computer at ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...